Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCX-020 in Advanced or Metastatic Solid Tumors
NCT07238075Phase 1Recruiting
- Sponsor
- Adcytherix
- Start
- Feb 2026
- Primary completion
- Jul 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of ADCX-020 in solid tumor (2 arms), sponsored by Adcytherix. Primary endpoints: Safety and Tolerability, Maximum Tolerated Dose and 2 more. Started Feb 2026; status: recruiting.
02
Drugs
ADCX-020
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07238075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238075.